Monday, November 08, 2021 7:05:18 AM
Showtime this week! Brilacidin is a BEAST. Remdesivir needs Brilicidin to remain relevant and in the market but Brilacidin does not need Remdesivir. Gilead has the opportunity to remain relevant and go down in history as the company that helped end the pandemic, or the company that missed the greatest opportunity.
Recent GILD News
- FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) • Business Wire • 05/22/2026 06:00:00 PM
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors • Business Wire • 05/22/2026 11:47:00 AM
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology • Business Wire • 05/21/2026 09:00:00 PM
- Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio • Business Wire • 05/21/2026 01:30:00 PM
- Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease • Business Wire • 05/21/2026 07:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:15:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:50:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:45:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 08:15:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:09:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:07:18 PM
- Gilead Prices $3 Billion of Senior Unsecured Notes • Business Wire • 05/15/2026 01:21:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/14/2026 09:11:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/14/2026 12:46:00 PM
- Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 • Business Wire • 05/13/2026 12:30:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/08/2026 09:00:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 09:13:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 09:12:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:03:01 PM
- Gilead Sciences Announces First Quarter Financial Results • Business Wire • 05/07/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:40:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:36:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:31:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:28:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:25:01 PM
